 Scaling The Peaks Biotech Stocks Hitting 52-week Highs Aug. 5 ABIOMED, Inc. NASDAQ: ABMD Aerpio Pharmaceuticals Inc NASDAQ: ARPO announced a U.S. government grant for a midstage COVID-19 treatment study Allovir Inc NASDAQ: ALVR went public Thursday Annexon Inc NASDAQ: ANNX Axonics Modulation Technologies Inc NASDAQ: AXNX Biofrontera AG NASDAQ: BFRA Cardiff Oncology Inc NASDAQ: CRDF CareDx Inc NASDAQ: CDNA reacted to second-quarter results DarioHealth Corp NASDAQ: DRIO DexCom, Inc. NASDAQ: DXCM Emergent Biosolutions Inc NYSE: EBS Fulgent Genetics Inc NASDAQ: FLGT reacted to second-quarter results GenMark Diagnostics, Inc NASDAQ: GNMK announced second-quarter results Hologic, Inc. NASDAQ: HOLX Horizon Therapeutics PLC NASDAQ: HZNP Illumina, Inc. NASDAQ: ILMN Immunomedics, Inc. NASDAQ: IMMU Inari Medical Inc NASDAQ: NARI Inozyme Pharma Inc NASDAQ: INZY Inspire Medical Systems Inc NYSE: INSP announced second-quarter results iTeos Therapeutics Inc NASDAQ: ITOS Meridian Bioscience, Inc. NASDAQ: VIVO NeoGenomics, Inc. NASDAQ: NEO Novavax, Inc. NASDAQ: NVAX reported positive Phase 1 data for coronavirus vaccine OraSure Technologies, Inc. NASDAQ: OSUR PDL BioPharma Inc NASDAQ: PDLI Penumbra Inc NYSE: PEN Quidel Corporation NASDAQ: QDEL Renalytix AI PLC NASDAQ: RNLX Silk Road Medical Inc NASDAQ: SILK Shockwave Medical Inc NASDAQ: SWAV Sorrento Therapeutics Inc NASDAQ: SRNE Twist Bioscience Corp NASDAQ: TWST Unity Biotechnology Inc NASDAQ: UBX Zoetis Inc NYSE: ZTSDown In The Dumps Biotech Stocks Hitting 52-week Lows Aug. 5 Intec Pharma Ltd NASDAQ: NTEC reacted to second-quarter results Nkarta Inc NASDAQ: NKTXStocks In Focus Aptinyx Finds Follow-Up Buying After RD Event Aptinyx Inc NASDAQ: APTX hosted a post-traumatic stress disorder RD event, where a psychiatry and PTSD key opinion leader reviewed the PTSD treatment landscape, preclinical data supporting NYX-783 for PTSD indication and the clinical design and expectations for the ongoing Phase 2 PTSD study, which is now expected to read out in fourth quarter.The company also announced plans to restart some of clinical trials that were paused due to COVID-19.The stock was advancing 19.38 to 4.65 in premarket trading Thursday.FDA Approves GlaxoSmithKlines Monotherapy Treatment of Multiple Myeloma In Second-Line Settings GlaxoSmithKline plc NYSE: GSK said the FDA approved Blenrep as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent.The stock was slipping 0.83 to 40.87 in premarket trading Thursday.See also: The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings Novartis Announces Publication Of Positive Results For Multiple Sclerosis Study Novartis AG NYSE: NVS said the New England Journal of Medicine published the positive results from the ASCLEPIOS I and II studies evaluating the safety and efficacy of ofatumumab 20mg monthly subcutaneous injections versus teriflunomide 14mg oral tablets taken once daily in adults with relapsing forms of multiple sclerosis.Both studies met the primary endpoints where ofatumumab showed a significant reduction in the number of confirmed relapses, evaluated as the annualized relapse rate.Anavexs Investigational Alzheimers Drug Approved For Continued Use Under Special Access Scheme In Australia Anavex Life Sciences Corp NASDAQ: AVXL said patients from the ANAVEX2-73-003 Phase 2a Alzheimers disease trial will continue treatment with ANAVEX2-73 through the Australian Government Department of Health - Therapeutic Goods Administration compassionate use Special Access Scheme following completion of over five years of daily dosing of the investigational therapy and recommendation by their physicians.The TGA compassionate use special access was issued based on the safety profile of ANAVEX2-73, as well as clinical evidence that it may benefit patients.In premarket trading Thursday, the stock was advancing 18.68 to 5.40.Anika Appoints Michael Levitz As CFO Anika Therapeutics Inc NASDAQ: ANIK announced the appointment of Michael Levitz as EVP, CFO and treasurer beginning Aug. 10, replacing Sylvia Cheung, who will continue in an advisory capacity for a period.Caladrius CFO To Depart Caladrius Biosciences Inc NASDAQ: CLBS said CFO Joseph Talamo has tendered his resignation in order to explore opportunities outside of Caladrius. Talamo will continue to serve as CFO until Aug. 21, the company said. Caladrius said it has initiated a search to identify qualified candidates to fill the permanent CFO position.The stock was slipping 8.46 to 2.38 in premarket trading Thursday.Earnings Orasures second-quarter revenue fell 25 year-over-year to 29.3 million, and the company reversed from a profit of 7 cents per share to a loss of 16 cents per share. Analysts, on average, estimated a loss of 9 cents per share.The stock was down 20.38 to 15.59 in after-hours trading.ADMA Biologics Inc NASDAQ: ADMA said its second-quarter revenue jumped 19.4 to 7.79 million and its loss per share narrowed from 25 cents to 23 cents. Analysts expected a narrower loss of 16 cents per share.The stock was moving down 14.33 to 3.05 in premarket trading Thursday.MannKind Corporation NASDAQ: MNKD reported second-quarter revenue that was almost flat year-over-year at 15.1 million. The net loss per share narrowed from 7 cents to 5 cents, in line with the consensus estimate.In premarket trading Thursday, the stock was plunging 8.6 to 1.70.Offerings Horizon Therapeutics said it plans to offer 700 million of its ordinary shares in an underwritten public offering. It intends to use the net proceeds to fund future acquisitions or licenses of, or investments.The stock was sliding 4.08 to 73.26 in premarket trading Thursday.DiaMedica Therapeutics Inc NASDAQ: DMAC said it intends to offer its common shares in an underwritten public offering. All of the common shares will be offered by the company. DiaMedica said it intends to use the net proceeds from the offering to continue its clinical and product development activities, and for other working capital and general corporate purposes.On The Radar Earnings Polarityte Inc NASDAQ: PTE before the market open Mylan NV NASDAQ: MYL before the market open Menlo Therapeutics Inc NASDAQ: MNLO before the market open Mediwound Ltd NASDAQ: MDWD before the market open Synlogic Inc NASDAQ: SYBX before the market open Zoetis Inc NYSE: ZTS before the market open TherapeuticsMD Inc NASDAQ: TXMD before the market open Ironwood Pharmaceuticals, Inc. NASDAQ: IRWD before the market open Syneos Health Inc NASDAQ: SYNH before the market open Orthofix Medical Inc NASDAQ: OFIX before the market open Eloxx Pharmaceuticals Inc NASDAQ: ELOX before the market open Dicerna Pharmaceuticals Inc NASDAQ: DRNA before the market open Alnylam Pharmaceuticals, Inc. NASDAQ: ALNY before the market open Athenex Inc NASDAQ: ATNX before the market open Amneal Pharmaceuticals Inc NYSE: AMRX before the market open Bristol-Myers Squibb Co NYSE: BMY before the market open Agenus Inc NASDAQ: AGEN before the market open ABIOMED, Inc. NASDAQ: ABMD before the market open BioCryst Pharmaceuticals, Inc. NASDAQ: BCRX before the market open AMAG Pharmaceuticals, Inc. NASDAQ: AMAG before the market open Galmed Pharmaceuticals Ltd NASDAQ: GLMD before the market open PDL BioPharma Inc NASDAQ: PDLI after the close Syndax Pharmaceuticals Inc NASDAQ: SNDX after the close Regenxbio Inc NASDAQ: RGNX after the close Dynavax Technologies Corporation NASDAQ: DVAX after the close Accelerate Diagnostics Inc NASDAQ: AXDX after the close Adamas Pharmaceuticals Inc NASDAQ: ADMS after the close Achieve Life Sciences Inc NASDAQ: ACHV after the close Acceleron Pharma Inc NASDAQ: XLRN after the close Coherus Biosciences Inc NASDAQ: CHRS after the close Puma Biotechnology Inc NASDAQ: PBYI after the close Axonics Modulation Technologies Inc NASDAQ: AXNX after the close Theravance Biopharma Inc NASDAQ: TBPH after the close Iovance Biotherapeutics Inc NASDAQ: IOVA after the close Glaukos Corp NYSE: GKOS after the close CytomX Therapeutics Inc NASDAQ: CTMX after the close Cytokinetics, Inc. NASDAQ: CYTK after the close Insulet Corporation NASDAQ: PODD after the close Chembio Diagnostics Inc NASDAQ: CEMI after the close Exelixis, Inc. NASDAQ: EXEL after the close Editas Medicine Inc NASDAQ: EDIT after the close FibroGen, Inc. NASDAQ: FGEN after the close Guardant Health Inc NASDAQ: GH after the close GW Pharmaceuticals PLC- ADR NASDAQ: GWPH after the close PRA Health Sciences Inc NASDAQ: PRAH after the close Illumina, Inc. NASDAQ: ILMN after the close Insmed Incorporated NASDAQ: INSM after the close Pfenex Inc NYSE: PFNX after the close ZIOPHARM Oncology Inc. NASDAQ: ZIOP after the close Spero Therapeutics Inc NASDAQ: SPRO after the close NovaBay Pharmaceuticals, Inc. NYSE: NBY after the close Opiant Pharmaceuticals Inc NASDAQ: OPNT after the close Nektar Therapeutics NASDAQ: NKTR after the closeIPOs Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, priced its initial public offering of 8. 